PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-11.65%
Negative revenue growth while CVE stands at 11.11%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-22.33%
Negative gross profit growth while CVE is at 0.15%. Joel Greenblatt would examine cost competitiveness or demand decline.
-27.12%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-27.12%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
0.59%
Positive net income growth while CVE is negative. John Neff might see a big relative performance advantage.
2.40%
Positive EPS growth while CVE is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
2.42%
Positive diluted EPS growth while CVE is negative. John Neff might view this as a strong relative advantage in controlling dilution.
-1.30%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-1.54%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
-0.12%
Dividend reduction while CVE stands at 120.18%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
52.98%
OCF growth 1.25-1.5x CVE's 45.82%. Bruce Berkowitz would see if superior pricing or efficient operations explain the gap.
480.44%
FCF growth above 1.5x CVE's 85.83%. David Dodd would verify if the firm’s strategic investments yield superior returns.
-22.38%
Negative 10Y revenue/share CAGR while CVE stands at 8.98%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
11.78%
5Y revenue/share CAGR under 50% of CVE's 65.97%. Michael Burry would suspect a significant competitive gap or product weakness.
27.55%
3Y revenue/share CAGR at 50-75% of CVE's 45.37%. Martin Whitman would question if the firm lags behind competitor innovations.
-26.83%
Negative 10Y OCF/share CAGR while CVE stands at 3.03%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
15.45%
Below 50% of CVE's 45.49%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
31.03%
3Y OCF/share CAGR under 50% of CVE's 122.48%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
-30.15%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
4.99%
Positive 5Y CAGR while CVE is negative. John Neff might view this as a strong mid-term relative advantage.
261.68%
3Y net income/share CAGR 50-75% of CVE's 384.39%. Martin Whitman might see a lagging edge in short-term profitability vs. the competitor.
-15.54%
Negative equity/share CAGR over 10 years while CVE stands at 17.16%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
7.00%
5Y equity/share CAGR above 1.5x CVE's 4.12%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
155.92%
3Y equity/share CAGR above 1.5x CVE's 37.81%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
-12.18%
Cut dividends over 10 years while CVE stands at 20.30%. Joel Greenblatt suspects a weaker ability to return capital vs. the competitor.
227.32%
Below 50% of CVE's 533.15%. Michael Burry worries the firm returns far less capital to shareholders over 5 years.
207.52%
Below 50% of CVE's 1364.81%. Michael Burry suspects the firm invests elsewhere or can’t match the competitor’s dividend policy.
-2.00%
Firm’s AR is declining while CVE shows 2.29%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
No Data
No Data available this quarter, please select a different quarter.
-0.13%
Negative asset growth while CVE invests at 1.83%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
1.97%
1.25-1.5x CVE's 1.40%. Bruce Berkowitz sees if the firm's capital management strategies surpass the competitor's approach.
-1.69%
We’re deleveraging while CVE stands at 1.89%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
-14.44%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.